PAR IO: A COST ANALYSIS OF CELECOXIB VERSUS DICLOFENAC PLUS OMEPRAZOLE FORTHE TREATMENT OF ARTHRITIS IN A GROUP OF HIGH-RISK CHINESE PATIENTS
2003
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI